Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2

MLA

Amanda J. Walker, et al. “Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2.” Clinical Cancer Research, vol. 16, Jan. 2010, pp. 664–72. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....816c5aa9291a73d57d4ea8ff9d65fa76&authtype=sso&custid=ns315887.

APA

Amanda J. Walker, Herbert L. Kotz, Elise C. Kohn, Katherine R. Calvo, Bradford J. Wood, Peter L. Choyke, Lori M. Minasian, Christina M. Annunziata, Minshu Yu, Seth M. Steinberg, & Daniel Kimm. (2010). Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2. Clinical Cancer Research, 16, 664–672.

Chicago

Amanda J. Walker, Herbert L. Kotz, Elise C. Kohn, Katherine R. Calvo, Bradford J. Wood, Peter L. Choyke, Lori M. Minasian, et al. 2010. “Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2.” Clinical Cancer Research 16 (January): 664–72. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....816c5aa9291a73d57d4ea8ff9d65fa76&authtype=sso&custid=ns315887.